Dr. Perl Discusses the Impact of CAR T-Cell Therapy on ALL

Video

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with acute lymphoblastic leukemia (ALL).

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with acute lymphoblastic leukemia (ALL).

Historically, there has not been an effective salvage therapy for patients with ALL. The CD19-directed therapies have changed that process, whether it is with blinatumomab (Blincyto) or CAR T-cell therapies, explains Perl.

There are high rates of response and durable responses with CD19-directed therapies. With CAR T-cell therapy, not all patients with ALL need a subsequent transplant because patients who achieve durable responses and persistence of their CAR T cells can live in sustained remissions without additional therapy.

According to Perl, patients who have had salvage therapy and have not responded continue to respond to CAR T-cell therapy. Having a different mechanism of modality has changed the treatment landscape for this patient population.

The FDA approved tisagenlecleucel (Kymriah) in patients with ALL back in August 2017. Investigators concluded that tisagenlecleucel was associated with clinically meaningful remissions. The estimated relapse-free rate among responders at month 6 was 75.4% (95% CI, 57.2-86.7). The median duration of response was not reached at a median follow-up of 4.8 months.

Recent Videos
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
© 2025 MJH Life Sciences

All rights reserved.